To investigate the correlation of the COX-2, CD31 and CD105 expression and the staging or prognosis of gastric cancer.

Immunohistochemistry was used to detect the expression levels of COX-2, CD31 and CD105 in 48 patients underwent radical gastrectomy from January 2016 to April 2018. Statistical analysis was performed by using SPSS 19.0 statistical software. The positive rates of CD31, CD105 and COX-2 expression were examined by using χ² test, and the correlation test was performed by using Spearman correlation analysis. A P value < 0.05 was considered as statistically significant difference.

The expression of COX-2, CD31 and CD105 was significantly correlated with the staging and prognosis of gastric cancer (P<0.05), but not with age, sex, tumor size and tumor location of these patients (P>0.05). The positive expression rate of COX-2 in gastric cancers was 76.5%, while the positive expression rates of CD31 and CD105 in gastric cancers were 68.8% and 70.8%, respectively. There was a correlation between COX-2 expression and vascular marker proteins CD31 (r=0.532, P=0.032) and CD105 (r=0.544, P=0.029).

COX-2, CD31 and CD105 are highly expressed in gastric cancer tissues. The expression of COX-2 is correlated with the expression of CD31 and CD105 in vascular markers which could be used as a clinical indicator for judging the staging and prognosis of gastric cancer.